Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridioides difficile toxin A (TcdA) is a major virulence factor responsible for the clinical manifestations of C. difficile infection (CDI), including diarrhea and colitis [1]. The C-terminal repeat domain, frequently termed the combined repetitive oligopeptides (CROPs) domain, is the region of the toxin responsible for binding to carbohydrate receptors on the surface of host intestinal epithelial cells [2]. This domain consists of multiple repetitive sequences that form a solenoid-like structure, facilitating multivalent binding to glycans such as the Lewis X and Y antigens [3]. Once the CROPs domain anchors the toxin to the cell membrane, the toxin is internalized via receptor-mediated endocytosis, leading to the glucosylation of host Rho GTPases and subsequent cell death [4]. Because this domain is essential for the initial step of toxin entry, it has become a primary target for therapeutic intervention, including neutralizing monoclonal antibodies like actoxumab and various vaccine candidates designed to elicit a protective immune response [5]. [1] UniProt P16154 (TCDA_CLODI). [2] Greco et al. (2006) PMID: 16412602. [3] Voth & Ballard (2005) PMID: 15659137. [4] Jank & Aktories (2013) PMID: 23595305. [5] Gerding et al. (2018) PMID: 29562316.
Neutralization of toxin binding to host cell surface receptors, thereby preventing toxin internalization and subsequent cellular damage.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridioides difficile toxin A combined repetitive oligopeptides domain (TcdA-CROP).